Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751529 · ClinicalTrials.gov registry record · Early Phase 1
Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer
A Early Phase 1 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
NCT01751529 is a Early Phase 1 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 48 participants.
The verdict
NCT01751529, a Early Phase 1 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This prospective pilot study is designed to evaluate the accuracy of contrast-enhanced ultrasound when used to evaluate renal lesions in two different populations; patients with known renal tumors (Cohort 1) and patients with a risk factor for renal malignancy in whom their screening ultrasound shows an indeterminate or possibly malignant renal mass (Cohort 2).
Interventions
- DRUG Perflutren lipid
- PROCEDURE Contrast-enhanced Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01751529
The ClinicalTrials.gov registry entry for NCT01751529 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Perflutren lipid is the first listed.
NCT01751529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01751529 about?
NCT01751529 is a clinical study titled "Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer". This prospective pilot study is designed to evaluate the accuracy of contrast-enhanced ultrasound when used to evaluate renal lesions in two different populations; patients with known renal tumors (Cohort 1) and patients with a risk factor for renal malignancy in whom their screening ultrasound show...
What is the current status of trial NCT01751529?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2013-05. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01751529?
The interventions under investigation include: Perflutren lipid (DRUG), Contrast-enhanced Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT01751529?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.